Volume | 46,366 |
|
|||||
News | - | ||||||
Day High | 0.38 | Low High |
|||||
Day Low | 0.3354 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Galmed Pharmaceuticals Ltd | GLMD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.3487 | 0.3354 | 0.38 | 0.3684 | 0.3543 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
163 | 46,366 | $ 0.3529262 | $ 16,364 | - | 0.26 - 7.80 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:36:10 | 27 | $ 0.367 | USD |
Galmed Pharmaceuticals Ltd Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
621.6k | 1.68M | - | 0 | -6.91M | -4.11 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Galmed Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLMD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.40465 | 0.44 | 0.3301 | 0.3996425 | 162,158 | -0.05365 | -13.26% |
1 Month | 0.3152 | 0.44 | 0.30 | 0.3689874 | 278,543 | 0.0358 | 11.36% |
3 Months | 0.399 | 0.4688 | 0.30 | 0.3547976 | 219,587 | -0.048 | -12.03% |
6 Months | 0.40 | 0.47 | 0.26 | 0.3719428 | 192,811 | -0.049 | -12.25% |
1 Year | 4.518 | 7.80 | 0.26 | 1.98 | 228,606 | -4.17 | -92.23% |
3 Years | 46.05 | 61.20 | 0.26 | 17.57 | 171,249 | -45.70 | -99.24% |
5 Years | 123.90 | 127.65 | 0.26 | 35.27 | 154,497 | -123.55 | -99.72% |
Galmed Pharmaceuticals Description
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. |